These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 15544993)
1. [Hypoxia, HIF1alpha and estrogen receptor]. Massaad-Massade L Bull Cancer; 2004 Sep; 91(9):677-83. PubMed ID: 15544993 [TBL] [Abstract][Full Text] [Related]
2. [Cellular and tissue hypoxia--role of the von Hippel Lindau gene and hypoxia-inducible factor-1]. Sýkora V; Necas E Cas Lek Cesk; 2003; 142(10):595-8. PubMed ID: 14635422 [TBL] [Abstract][Full Text] [Related]
3. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Blancher C; Moore JW; Robertson N; Harris AL Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776 [TBL] [Abstract][Full Text] [Related]
4. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Maynard MA; Ohh M Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728 [TBL] [Abstract][Full Text] [Related]
5. HIF-1: an oxygen response system with special relevance to the kidney. Maxwell P J Am Soc Nephrol; 2003 Nov; 14(11):2712-22. PubMed ID: 14569080 [No Abstract] [Full Text] [Related]
6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
7. Angiogenesis: how a tumor adapts to hypoxia. Richard DE; Berra E; Pouysségur J Biochem Biophys Res Commun; 1999 Dec; 266(3):718-22. PubMed ID: 10603309 [TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362 [TBL] [Abstract][Full Text] [Related]
9. Cutting to the quick: proteolytic control of oxygen sensors. Dean RT Redox Rep; 1999; 4(4):135-6. PubMed ID: 10658818 [No Abstract] [Full Text] [Related]
10. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. Wenger RH FASEB J; 2002 Aug; 16(10):1151-62. PubMed ID: 12153983 [TBL] [Abstract][Full Text] [Related]
11. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Yu F; White SB; Zhao Q; Lee FS Cancer Res; 2001 May; 61(10):4136-42. PubMed ID: 11358837 [TBL] [Abstract][Full Text] [Related]
12. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597 [TBL] [Abstract][Full Text] [Related]
13. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function. Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Tanimoto K; Makino Y; Pereira T; Poellinger L EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113 [TBL] [Abstract][Full Text] [Related]
15. Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts. Yen ML; Su JL; Chien CL; Tseng KW; Yang CY; Chen WF; Chang CC; Kuo ML Mol Pharmacol; 2005 Oct; 68(4):1061-73. PubMed ID: 15998873 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766 [TBL] [Abstract][Full Text] [Related]
19. Cancer: cues for migration. Bernards R Nature; 2003 Sep; 425(6955):247-8. PubMed ID: 13679899 [No Abstract] [Full Text] [Related]